Edwards Lifesciences Reports Third Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall St set for higher open tech gains offset bond-market jitters
- Oil prices rise as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
Bernstein SocGen Group Upgrades Edwards Lifesciences (EW) to Market Perform
October 28, 2024 8:19 AM EDTBernstein SocGen Group analyst Lee Hambright upgraded Edwards Lifesciences (NYSE: EW) from to Market Perform.
The analyst comments "Our previous Underperform call on EW was based on the view that the TAVR market was experiencing slowing growth and increased competition. Now as... More
BTIG Reiterates Neutral Rating on Edwards Lifesciences (EW)
October 25, 2024 5:22 AM EDTBTIG analyst Marie Thibault reiterated a Neutral rating on Edwards Lifesciences (NYSE: EW).
The analyst comments "There were a few moving parts with this quarter's print following the sale of the Critical Care business in September as well as the discontinuation of a small non-core product group in the Surgical Structural Heart business that generates ~$60-70M in annual sales. Excluding these items, EW grew revenue by 9.6% y/y CC in Q3 and reported adj. EPS of $0.67. Total TAVR sales of $1.023B were $13M above consensus of $1.010B (+6.5% y/y rep., +7.2% CC).... More
